178 related articles for article (PubMed ID: 38315575)
1. Beneficial effects of simultaneously targeting calorie intake and calorie efficiency in diet-induced obese mice.
Chen SY; Telfser AJ; Olzomer EM; Vancuylenberg CS; Zhou M; Beretta M; Li C; Alexopoulos SJ; Turner N; Byrne FL; Santos WL; Hoehn KL
Clin Sci (Lond); 2024 Feb; 138(4):173-187. PubMed ID: 38315575
[TBL] [Abstract][Full Text] [Related]
2. Targeting negative energy balance with calorie restriction and mitochondrial uncoupling in db/db mice.
Chen SY; Beretta M; Olzomer EM; Shah DP; Wong DYH; Alexopoulos SJ; Aleksovska I; Salamoun JM; Garcia CJ; Cochran BJ; Rye KA; Smith GC; Byrne FL; Morris MJ; Santos WL; Cantley J; Hoehn KL
Mol Metab; 2023 Mar; 69():101684. PubMed ID: 36731653
[TBL] [Abstract][Full Text] [Related]
3. Head-to-head comparison of BAM15, semaglutide, rosiglitazone, NEN, and calorie restriction on metabolic physiology in female db/db mice.
Chen SY; Beretta M; Olzomer EM; Alexopoulos SJ; Shah DP; Byrne FL; Salamoun JM; Garcia CJ; Smith GC; Larance M; Philp A; Turner N; Santos WL; Cantley J; Hoehn KL
Biochim Biophys Acta Mol Basis Dis; 2024 Jan; 1870(1):166908. PubMed ID: 37793464
[TBL] [Abstract][Full Text] [Related]
4. Oral Semaglutide under Human Protocols and Doses Regulates Food Intake, Body Weight, and Glycemia in Diet-Induced Obese Mice.
Rakhat Y; Wang L; Han W; Rustemova A; Kulzhanova N; Yamada Y; Yabe D; Seino Y; Yada T
Nutrients; 2023 Aug; 15(17):. PubMed ID: 37686797
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial uncoupler BAM15 reverses diet-induced obesity and insulin resistance in mice.
Alexopoulos SJ; Chen SY; Brandon AE; Salamoun JM; Byrne FL; Garcia CJ; Beretta M; Olzomer EM; Shah DP; Philp AM; Hargett SR; Lawrence RT; Lee B; Sligar J; Carrive P; Tucker SP; Philp A; Lackner C; Turner N; Cooney GJ; Santos WL; Hoehn KL
Nat Commun; 2020 May; 11(1):2397. PubMed ID: 32409697
[TBL] [Abstract][Full Text] [Related]
6. Effect of combined administration of Acyl-CoA: Cholesterol acyltransferase 1 inhibitor and glucagon-like peptide 1 receptor agonist on a rodent model of diet-induced obesity.
Kim SQ; Kim J; Choi M; Kim Y; Kim S; Kim KH
Biochem Biophys Res Commun; 2023 Dec; 688():149164. PubMed ID: 37951155
[TBL] [Abstract][Full Text] [Related]
7. Semaglutide alleviates gut microbiota dysbiosis induced by a high-fat diet.
Duan X; Zhang L; Liao Y; Lin Z; Guo C; Luo S; Wang F; Zou Z; Zeng Z; Chen C; Qiu J
Eur J Pharmacol; 2024 Apr; 969():176440. PubMed ID: 38402930
[TBL] [Abstract][Full Text] [Related]
8. Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism.
Nunn E; Jaiswal N; Gavin M; Uehara K; Stefkovich M; Drareni K; Calhoun R; Lee M; Holman CD; Baur JA; Seale P; Titchenell PM
Mol Metab; 2024 Feb; 80():101880. PubMed ID: 38218536
[TBL] [Abstract][Full Text] [Related]
9. Semaglutide (GLP-1 receptor agonist) stimulates browning on subcutaneous fat adipocytes and mitigates inflammation and endoplasmic reticulum stress in visceral fat adipocytes of obese mice.
Martins FF; Marinho TS; Cardoso LEM; Barbosa-da-Silva S; Souza-Mello V; Aguila MB; Mandarim-de-Lacerda CA
Cell Biochem Funct; 2022 Dec; 40(8):903-913. PubMed ID: 36169111
[TBL] [Abstract][Full Text] [Related]
10. Weight Changes and Metabolic Outcomes in Calorie-Restricted Obese Mice Fed High-Fat Diets Containing Corn or Flaxseed Oil: Physiological Role of Sugar Replacement with Polyphenol-Rich Grape.
Ansar H; Zamaninour N; Djazayery A; Pishva H; Vafa M; Mazaheri Nezhad Fard R; Dilmaghanian A; Mirzaei K; Shidfar F
J Am Coll Nutr; 2017 Aug; 36(6):422-433. PubMed ID: 28665260
[TBL] [Abstract][Full Text] [Related]
11. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
Komiya C; Tsuchiya K; Shiba K; Miyachi Y; Furuke S; Shimazu N; Yamaguchi S; Kanno K; Ogawa Y
PLoS One; 2016; 11(3):e0151511. PubMed ID: 26977813
[TBL] [Abstract][Full Text] [Related]
12. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.
Blundell J; Finlayson G; Axelsen M; Flint A; Gibbons C; Kvist T; Hjerpsted JB
Diabetes Obes Metab; 2017 Sep; 19(9):1242-1251. PubMed ID: 28266779
[TBL] [Abstract][Full Text] [Related]
13. Obese mice weight loss role on nonalcoholic fatty liver disease and endoplasmic reticulum stress treated by a GLP-1 receptor agonist.
Pontes-da-Silva RM; de Souza Marinho T; de Macedo Cardoso LE; Mandarim-de-Lacerda CA; Aguila MB
Int J Obes (Lond); 2022 Jan; 46(1):21-29. PubMed ID: 34465857
[TBL] [Abstract][Full Text] [Related]
14. Treatment sequencing using the dual amylin and calcitonin receptor agonist KBP-336 and semaglutide results in durable weight loss.
Thorsø Larsen A; Karsdal MA; Henriksen K
Eur J Pharmacol; 2023 Sep; 954():175837. PubMed ID: 37329973
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Beneficial Metabolic Effects of Liraglutide and Semaglutide in Male C57BL/6J Mice.
Liu D; Gu J; Shao W; Pang J; Qian X; Jin T
Can J Diabetes; 2022 Apr; 46(3):216-224.e2. PubMed ID: 35568421
[TBL] [Abstract][Full Text] [Related]
16. An Effective Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Improves Sarcopenic Obesity in Obese Mice by Modulating Skeletal Muscle Metabolism.
Ren Q; Chen S; Chen X; Niu S; Yue L; Pan X; Li Z; Chen X
Drug Des Devel Ther; 2022; 16():3723-3735. PubMed ID: 36304787
[TBL] [Abstract][Full Text] [Related]
17. Semaglutide Improves Liver Steatosis and De Novo Lipogenesis Markers in Obese and Type-2-Diabetic Mice with Metabolic-Dysfunction-Associated Steatotic Liver Disease.
Soto-Catalán M; Opazo-Ríos L; Quiceno H; Lázaro I; Moreno JA; Gómez-Guerrero C; Egido J; Mas-Fontao S
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474208
[TBL] [Abstract][Full Text] [Related]
18. Amylin improves the effect of leptin on insulin sensitivity in leptin-resistant diet-induced obese mice.
Kusakabe T; Ebihara K; Sakai T; Miyamoto L; Aotani D; Yamamoto Y; Yamamoto-Kataoka S; Aizawa-Abe M; Fujikura J; Hosoda K; Nakao K
Am J Physiol Endocrinol Metab; 2012 Apr; 302(8):E924-31. PubMed ID: 22275759
[TBL] [Abstract][Full Text] [Related]
19. BAM15-mediated mitochondrial uncoupling protects against obesity and improves glycemic control.
Axelrod CL; King WT; Davuluri G; Noland RC; Hall J; Hull M; Dantas WS; Zunica ER; Alexopoulos SJ; Hoehn KL; Langohr I; Stadler K; Doyle H; Schmidt E; Nieuwoudt S; Fitzgerald K; Pergola K; Fujioka H; Mey JT; Fealy C; Mulya A; Beyl R; Hoppel CL; Kirwan JP
EMBO Mol Med; 2020 Jul; 12(7):e12088. PubMed ID: 32519812
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer growth and proliferation is suppressed by the mitochondrial targeted furazano[3,4-b]pyrazine BAM15.
Zunica ERM; Axelrod CL; Cho E; Spielmann G; Davuluri G; Alexopoulos SJ; Beretta M; Hoehn KL; Dantas WS; Stadler K; King WT; Pergola K; Irving BA; Langohr IM; Yang S; Hoppel CL; Gilmore LA; Kirwan JP
Cancer Metab; 2021 Oct; 9(1):36. PubMed ID: 34627389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
